ZNF614

Across TCGA pan-cancer cohorts, ZNF614 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF614 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ZNF614 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF614 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

ACC, UCEC, and STAD are the cancer types where ZNF614 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.273	0.802	.017	15	view →
UCEC	DFS	Median	All	0.959	0.624	.017	6	view →
STAD	DFS	Median	IV	1.000	0.284	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF614–ACC (OS)

Open the ACC breakdown →